Certara (NASDAQ:CERT) Issues FY 2025 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.420-0.460 for the period, compared to the consensus earnings per share estimate of 0.500. The company issued revenue guidance of $415.0 million-$425.0 million, compared to the consensus revenue estimate of $422.4 million.

Certara Stock Performance

CERT stock traded down $0.05 during midday trading on Wednesday, hitting $12.33. The stock had a trading volume of 1,212,151 shares, compared to its average volume of 1,273,763. Certara has a 52 week low of $9.41 and a 52 week high of $19.87. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a 50-day simple moving average of $12.36 and a 200 day simple moving average of $11.63. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of -61.65, a P/E/G ratio of 9.29 and a beta of 1.57.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on CERT. Robert W. Baird lowered their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Barclays lowered their price objective on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Certara presently has a consensus rating of “Hold” and an average price target of $15.92.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.